This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment (BONA)

This study has been completed.
Information provided by:
Bayer Identifier:
First received: July 29, 2010
Last updated: September 6, 2012
Last verified: September 2012
Adherence (or compliance with) a medication regimen is generally defined as the extent to which patients take medication as prescribed by their health care providers. The adherence to medications has close relation to effectiveness of the therapy. The primary objective of this study is to observe the adherence to treatment with oral clodronate (PDC, proportion of days covered, number of days in which clodronate is taken according to treating physician recommendation) in patients with malignancy. The secondary "hypothesis generating" objective is to describe the relation between adherence to treatment with oral clodronate and efficacy of the therapy (skeletal events, pain).

Condition Intervention
Breast Neoplasms Prostatic Neoplasms Multiple Myeloma Osteolysis Drug: Clodronate (Bonefos, BAY94-8393)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: BONA (Adherence of Patients to Bonefos Therapy). Prospective Observational Non-interventional Study of Adherence of Patients to Bonefos Medication in Relation to Analgesic Effect and Incidence of Skeletal Events

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Adherence to treatment with oral clodronate (PDC, proportion of days covered). [ Time Frame: 12 months of therapy. ]

Secondary Outcome Measures:
  • Efficacy evaluation of the therapy based on incidence of skeletal events [ Time Frame: 12 months ]
  • Efficacy of the therapy in pain releif will be investigated exploratory based on questionnaire [ Time Frame: 12 months ]

Enrollment: 147
Study Start Date: January 2009
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Drug: Clodronate (Bonefos, BAY94-8393)
Random group of patients in oncology clinic


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Random group of patients in oncology clinic

Inclusion Criteria:

  • Diagnosis of breast cancer, prostate cancer, multiple myeloma and other skeletal events causing tumors
  • Bone metastases
  • Therapy with clodronate (1600 mg per day, 800 mg tablets) according to SmPC (Summary of Product Characteristics) Bonefos.
  • By agreeing to usage of patients diaries and goodwill with accounting of tablets

Exclusion Criteria:

  • According to SmPC (Summary of Product Characteristics) Bonefos.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01198457

Czech Republic
Many Locations, Czech Republic
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Medical Director, Bayer Healthcare AG Identifier: NCT01198457     History of Changes
Other Study ID Numbers: 14561
BO0910CZ ( Other Identifier: Company Internal )
Study First Received: July 29, 2010
Last Updated: September 6, 2012

Keywords provided by Bayer:

Additional relevant MeSH terms:
Multiple Myeloma
Breast Neoplasms
Prostatic Neoplasms
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Neoplasms by Site
Breast Diseases
Skin Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Diseases
Bone Resorption
Bone Diseases
Musculoskeletal Diseases
Clodronic Acid
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on September 21, 2017